The Trader Harbor
  • Business
  • Politics
  • World News
  • Stocks
  • Business
  • Politics
  • World News
  • Stocks

The Trader Harbor

Business

Kenvue stock drops 10% on report RFK Jr. will link autism to Tylenol use during pregnancy

by admin September 8, 2025
September 8, 2025
Kenvue stock drops 10% on report RFK Jr. will link autism to Tylenol use during pregnancy

Shares of Kenvue fell more than 10% on Friday after a report that Health Secretary Robert F. Kennedy Jr. will likely link autism to the use of the company’s pain medication Tylenol in pregnant women.

HHS will release the report that could draw that link this month, The Wall Street Journal reported on Friday.

That report will also suggest a medicine derived from folate — a water-soluble vitamin — can be used to treat symptoms of the developmental disorder in some people, according to the Journal.

In a statement, an HHS spokesperson said, “We are using gold-standard science to get to the bottom of America’s unprecedented rise in autism rates.”

“Until we release the final report, any claims about its contents are nothing more than speculation,” they added.

Tylenol could be the latest widely used and accepted treatment that Kennedy has undermined at the helm of HHS, which oversees federal health agencies that regulate drugs and other therapies. Kennedy has also taken steps to change vaccine policy in the U.S., and has amplified false claims about safe and effective shots that use mRNA technology.

Kennedy has made the disorder a key focus of HHS, pledging in April that the agency will “know what has caused the autism epidemic” by September and eliminate exposures. He also said that month that the agency has launched a “massive testing and research effort” involving hundreds of scientists worldwide that will determine the cause.

In a statement, Kenvue said it has “continuously evaluated the science and [continues] to believe there is no causal link” between the use of acetaminophen, the generic name for Tylenol, during pregnancy and autism.

The company added that the Food and Drug Administration and leading medical organizations “agree on the safety” of the drug, its use during pregnancy and the information provided on the Tylenol label.

The FDA website says the agency has not found “clear evidence” that appropriate use of acetaminophen during pregnancy causes “adverse pregnancy, birth, neurobehavioral, or developmental outcomes.” But the FDA said it advises pregnant women to speak with their health-care providers before using over-the-counter drugs.

The American College of Obstetricians and Gynecologists maintains that acetaminophen is safe during pregnancy when taken as directed and after consulting a health-care provider.

Some previous studies have suggested the drug poses risks to fetal development, and some parents have brought lawsuits claiming that they gave birth to children with autism after using it.

But a federal judge in Manhattan ruled in 2023 that some of those lawsuits lacked scientific evidence and later ended the litigation in 2024. Some research has also found no association between acetaminophen use and autism.

In a note on Friday, BNP Paribas analyst Navann Ty said the firm believes the “hurdle to proving causation [between the drug and autism] is high, particularly given that the litigation previously concluded in Kenvue’s favor.”

This post appeared first on NBC NEWS

0
FacebookTwitterGoogle +Pinterest
previous post
The Real Drivers of This Market: AI, Semis & Robotics
next post
From ‘legislative terrorists’ to center of Trump’s DC revolution: Where key conservative caucus is now

Related Posts

Trump Media shares rise again, jump 50% in...

May 2, 2024

How Trump was ‘orange-pilled’ by three bitcoiners in...

August 29, 2024

Dow tumbles 475 points, S&P 500 suffers worst...

April 15, 2024

Joann to shutter all 800 fabric stores after...

February 26, 2025

Fed holds interest rates but keeps door open...

August 2, 2024

TikTok says ban would cost U.S. small businesses...

December 10, 2024

There’s been a ‘meaningful shift’ in CEO confidence...

January 16, 2025

UnitedHealth CEO suddenly steps down for ‘personal reasons’

May 14, 2025

Boeing machinists on picket lines prepare for lengthy...

September 24, 2024

Federal prosecutors are examining financial transactions at Block,...

May 2, 2024

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • The Real Drivers of This Market: AI, Semis & Robotics

      September 9, 2025
    • S&P 500 Breaking Out Again: What This Means for Your Portfolio

      September 9, 2025
    • Supreme Court temporarily greenlights firing of Biden-appointed FTC commissioner

      September 9, 2025
    • LAPD ends Kamala Harris security after union backlash over elite officer use: report

      September 9, 2025
    • Federal appeals court upholds $83.3M E. Jean Carroll judgment against Trump

      September 9, 2025
    • Thune lays groundwork for nuclear option in Senate fight over Trump nominees

      September 9, 2025

    Categories

    • Business (1,381)
    • Politics (4,436)
    • Stocks (1,637)
    • Uncategorized (45)
    • World News (1,374)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: TheTraderHarbor, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 thetraderharbor.com | All Rights Reserved